Truist Securities analyst Asthika Goonewardene reiterated a Buy rating and $70.00 price target on Legend Biotech Corp. (NASDAQ: LEGN)

The analyst commented, "Legend reported Carvykti sales of $555M in 4Q25 and $1.9B for FY25, as previously announced, with LEGN's share amounting to $306.3M and $1,028.9M, respectively. Community or regional hospitals now represent ~1/3 of treatment centers that are administering Carvykti. Importantly, we infer from LEGN's comments that Raritan's full manufacturing slot capacity has been approved, which we think will unshackle 2-4L growth. Carvykti franchise became profitable in 2025 and Legend expects companywide profitability in 2026. Legend ended 2025 with $949M in cash and cash equivalents. The company also appears to be increasingly focused on in-vivo CAR-T approaches."

For an analyst ratings summary and ratings history on Legend Biotech Corp. click here. For more ratings news on Legend Biotech Corp. click here.

Shares of Legend Biotech Corp. closed at $19.14 yesterday.